See discussions, stats, and author profiles for this publication at: https://.researchgate.net/publication/15093941 Her-2/neu Expression in Node-negative Breast Cancer: Direct Tissue Quantitation by Computerized Image Analysis and Association of Overexpression with Increased Risk of Recurrent Di... ...
Her2neu scoreDFSOSTriple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in ...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cellsGeradts J., Leek R Harris A L Wilson K S
ER+ and HER2/neu-positive subtype ER+ and HER2/neu-negative subtype Basal-like breast cancer Breast cancer diagnosis A diagnostic delay, or the time between when you first notice symptoms and when you are diagnosed with breast cancer, determines how quickly you’re treated. The longer it tak...
A CASE OF METASTATIC BREAST CANCER WITH OUTGROWTH OF HER2–NEGATIVE CELLS AFTER ERADICATION OF HER2–POSITIVE CELLS BY HUMANIZED ANTI–HER2 MONOCLONAL ... K Kunitomo,S Inoue,F Ichihara,... 被引量: 0发表: 0年 Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid progn...
The tumour immune microenvironment is shaped by the crosstalk between cancer cells, immune cells, fibroblasts, endothelial cells and other stromal components. Although the immune tumour microenvironment (TME) serves as a source of therapeutic targets, it
As the original tumor was Her2 negative, if a genomic assay was then done on this patient, we would have identified the potential of CNS involvement. In conclusion, genomic assays should be routinely done on triple negative cancers. Keywords: triple negative, breast cancer, claudin high or low...
The peptide in development is based on a 2018 Cleveland Clinic discovery and serves as a proof-of-concept for this type of drug for triple-negative breast cancer.Triple-negative (ER-negative, PR-negative, HER2/neu not overexpressed) breast cancer has distinct clinical and pathologic featur...
A phase Ib study of pembrolizumab plus abemaciclib in heavily pretreated patients with PD-L1-positive estrogen receptor-positive/HER2-negative advanced cancer showed an acceptable safety profile and clinical activity (overall response rate [ORR] 14.3% at 16 weeks with a 75% disease control rate)63...